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Prevalence and pattern of hyperuricemia in a survey among inhabitants 
of Sokoto metropolis, north western Nigeria.
Abstract
Pbjective. Hyperuricemia is increasingly being recognized as a risk factor for cardiovascular, metabolic 
and renal diseases. Studies have revealed links between urate, cardiovascular events and metabolic 
syndrome with considerable ethnic and geographical variation. Although clinical features may develop in 
persons with hyperuricemia, more than 60% remain symptomatic. There are no definite criteria for 
therapeutic intervention in patients with asymptomatic hyperuricemia. The study attempts to determine 
the prevalence and pattern of hyperuricemia among inhabitants of Sokoto in a bid to identify associated 
factors and threshold for rational therapy. 
Methods. A cross sectional survey of 161 adults in which demographic indices including physical 
examination, anthropometric measurements were obtained with urine and blood samples taken for 
analysis. Statistical evaluation was done, using SPSS version 16 (SPSS Inc. Chicago, IL)
Results.  Hyperuricemia was documented in 20.5%, with male to female ratio of 2:1 and higher mean 
urate level in males. Urate level increased with age; ranging from 5.0mmol/L±1.8 among 20-29 years to 
6.5mmol/L±1.6 in those aged 50-59 years. Systemic hypertension, type2 DM, Obesity and kidney 
dysfunction were commoner among normouricemic than hyperuricemic subjects. 
Conclusions. Hyperuricemia is common, especially among male gender and advancing age. The 
association between hyperuricemia and cardiovascular events remains a contentious issue as prevalence 
of type2DM, obesity and kidney dysfunction were similar in hyperuricemic and normouricemic subjects. 
We could not determine threshold to commence treatment for elevated uric acid level.  A larger population  
and multicentre research is required to prove a link between hyperuricemia and some components of 
metabolic syndrome.
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Prévalence et motif de l'hyperuricémie dans une enquête auprès des 
habitants de la métropole de Sokoto, au nord ouest du Nigeria.
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Resume
Objectif. L'hyperuricémie est de plus en plus reconnu comme un facteur de risque pour cardiovasculaires, 
métaboliques et les maladies rénales. Des études ont révélé des liens entre l'urate, les événements 
cardiovasculaires et le syndrome métabolique avec une variation ethnique et géographique considérable. 
Bien que les caractéristiques cliniques peuvent se développer chez les personnes présentant une 
hyperuricémie, plus de 60% demeurent symptomatiques. Il n'y a pas de critères précis pour l'intervention 
thérapeutique chez les patients présentant une hyperuricémie asymptomatique. L'étude tente de 
déterminer la prévalence et les tendances de l'hyperuricémie chez les habitants de Sokoto, dans le but 
d'identifier les facteurs et les seuils associés pour la thérapie rationnelle.
Méthodes. Une enquête transversale de 161 adultes dans lequel les indices démographiques, y compris 
l'examen physique, les mesures anthropométriques ont été obtenus avec l'urine et de sang prélevés pour 
analyse. L'évaluation statistique a été effectuée à l'aide du logiciel SPSS version 16 (SPSS Inc. Chicago, 
IL)
Résultats. Hyperuricémie a été documentée dans 20,5%, avec ratio hommes-femmes de 2: 1 et plus le 
niveau moyen de l'urate chez les mâles. niveau de l'urate augmente avec l'âge; allant de 5,0 mmol / L ± 1,8 
entre 20-29 ans à 6,5 mmol / L ± 1,6 chez ceux âgés de 50-59 ans. L'hypertension systémique, type2 DM, 
l'obésité et la dysfonction rénale étaient plus fréquents chez les normouricemic que les sujets 
hyperuricémiques.
Conclusions. Hyperuricémie est fréquent, surtout chez le sexe masculin et l'âge avancé. L'association 
entre l'hyperuricémie et d'événements cardiovasculaires reste une question controversée que la 
prévalence des type2DM, l'obésité et la dysfonction rénale étaient similaires chez les sujets 
hyperuricémiques et normouricemic. Nous ne pouvions pas déterminer le seuil de commencer le 
traitement pour le niveau d'acide urique élevé. Une population plus importante et la recherche 
multicentrique est nécessaire de prouver un lien entre hyperuricémie et certains composants du syndrome 
métabolique.
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INTRODUCTION 
Elevated serum uric acid level is fast 
gaining prominence as a risk factor for 
cardiovascular, metabolic and kidney diseases 
(1,2). Hitherto, it was largely thought to be a 
consequence of these conditions or having 
indirect association with these diseases rather 
than playing an etiologic role (3). Hyperuricemia 
is currently not considered to be an important risk 
factor for metabolic syndrome, cardiovascular 
events and renal disorders by the American Heart 
Associat ion (AHA),  National  Kidney 
Foundation (NKF) and Joint National Committee 
(NJC) on prevention, detection, evaluation and 
treatment of hypertension (4,5,6). The link 
between elevated urate and cardiovascular events 
has been studied in general populations and in 
patients with type 2 diabetes, congestive cardiac 
failure, coronary heart disease and systemic 
 
hypertension (9,10). Multiple studies provide 
evidence that hyperuricemia is an independent 
.risk factor for cardiovascular mortality (11-14)
Studies from different parts of world 
have also revealed considerable ethnic and 
geographic variations in mean serum uric acid 
levels (15-17). The differences have been 
ascribed to genetic ,  physiologic and 
environmental factors which include age, sex, 
race, socioeconomic status, diet, systemic 
hypertension and alcohol intake (7,18). Global 
prevalence rate of hyperuricemia has been 
 
reported to be between 5% to 62% (7,18,19). In 
Nigeria, prevalence among diabetics from studies 
by Isezuo et al and Ogbera et al were 32.3% and 
 
25% respectively (20,21). Hyperuricemia is 
frequently seen in hypertensive patients and is 
often related to defect in renal urate clearance 
(18,22,23). Patients with hypertension and 
increased urate level have about 5 fold increased 
r isk  of  coronary ar tery  disease  and 
cerebrovascular disease as compared with 
patients with normal urate levels (24,25). Recent 
studies have documented association between 
urate level and hypertension, type 2 diabetes 
mellitus( DM),chronic kidney disease(CKD), 
heart failure, metabolic syndrome, obesity and 
cardiovascular events (11,17,21,25,26). Despite 
increasing incidence of gout and other uric acid 
 
related diseases (19), it has been found that 
persons with asymptomatic hyperuricemia are 
very common. Although clinical manifestations 
may develop in individuals with hyperuricemia at 
any point, more than 60% of such persons remain 
asymptomatic and without physical signs 
(18,22,24). Asymptomatic hyperuricemia has 
also been associated with some disorders which 
appear to be largely unrelated to crystal 
deposition (1,3,9,11,17). These disorders include 
hypertension, chronic kidney disease, 
cardiovascular disease and insulin resistance 
syndrome. A universally acceptable definition of 
hyperuricemia is not available because of the 
discrepancies observed in clinical features at 
varied levels of uric acid (18,22,25,27). However, 
physicochemical definition based upon the 
solubility limit of urate in body fluids 
corresponds to urate concentration greater than 
7mg/dL(416 µmol/L) as measured by automated 
enzymatic methods or 8mg/dL obtained with 
colorimetric methods (27,28).There is paucity of 
defini te  cr i ter ia  on which to decide 
commencement of medical treatment in 
individuals with asymptomatic hyperuricemia. 
This study is an attempt to determine the 
prevalence of hyperuricemia among inhabitants 
of Sokoto metropolis in a bid to identify threshold 
for rational therapy.
MATERIALS AND METHODS
This is a cross sectional survey carried 
out during the world kidney day 2013 celebration 
amongst the populace of Sokoto metropolis, 
North western Nigeria. Ethical approval was 
obtained from Usmanu Danfodiyo University 
Teaching Hospital, Sokoto while consent was 
obtained  the participants.
At the end of the survey, 161 participants 
were screened for cardiovascular and renal risk 
factors. Indices such as age, gender, occupation, 
educational level, diet and drug history were 
obtained through face to face interview. 
Similarly, history of smoking, alcohol 
consumption and chronic medical conditions 
such as for hypertension and diabetes were 
documented. All subjects had measurements of 
weight, standing height and BMI with readings 
taken to the nearest 0.1 kg and nearest 0.1 cm for 
weight and height respectively. Waist and hip 
circumference were measured and waist hip ratio 
determined. Blood pressure was measured in the 
sitting position after 5 minutes rest and average of 
two readings taken, using a mercury 
sphygmomanometer.
Five milliliters of venous blood and spot 
urine sample was collected from each participant. 
A dip stick method, using an Ames-Multistix 
(Combi-10) urinary reagent strip was utilized to 
analyze the urine samples. Both low and high 
power objective lens of light microscope were 
used to examine for casts, white blood cells, red 
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blood cells, epithelial cells and crystals.  The 
blood specimens were allowed to clot at room 
temperature for 30 minutes and sera were 
obtained after centrifugation at 1000 x g for 
10minutes. The sera were used for the evaluation 
of uric acid using Chiron express plus chemistry 
autoanalyser by Chiron diagnostics, USA. 
Subjects were considered to have hyperuricemia 
if the serum uric acid level was 416 µmol/L (7.0 
mg/dL) in males and 386 µmol/L (6.5 mg/dL) in 
females. These cutoff values are used to define 
hyperuricemia in our clinical laboratory.
All statistical analysis was performed 
using the SPSS program, version 16.0 (SPSS Inc, 
Chicago, IL). The data were presented as means ± 
SD or proportions. Categorical data were 
compared by means of Chi-square test and 
continuous variables by means of t-test. A p value 
of <0.05 was considered statistically significant.
RESULTS
A total of 161 subjects were studied with 
overall mean age of 28.48 (6.8). Males 
constituted 59%(n=95) of study subjects while 
females constituted 41%(n=66) with mean age of 
27.6(4.3) and 29.7(9.2) respectively. The clinical 
and biochemical characteristics in both genders 
are presented in table 1.  Means of waist 
circumference, waist hip ratio, systolic blood 
pressure diastolic blood pressure, fasting blood 
sugar and serum urea were similar between males 
and females. However, the mean BMI was higher 
in the females than in the males (p=0.04).  A 
higher percentage of males (29.3%) had 
significant proteinuria than females but the 
difference did not reach statistical significance. 
Nine females (5.6%) had hematuria which was 
not seen in any of the male participants.  
Hyperuricemia was found in 33 subjects (20.5%) 
with male to female ratio of 2:1. Males had a 
higher mean uric acid of 5.19 ± 1.76 than females 
4.89 ± 1.58, but the difference did not reach 
statistical significance, p-value>0.05. 
The distribution of serum uric acid by 
age group is shown in table 2. The serum uric acid 
appears to be increasing with age ranging from 
5.0 ±1.8mmol/L in those aged 20-29years to 6.5 
±1.6 mmol/L among participants in age group 50-
59 years. Comparison of subjects with 
h y p e r u r i c e m i a  a g a i n s t  t h o s e  w i t h  
normouricaemia is presented in table 3. The 
anthropometric parameters, blood pressure 
indices and biochemical parameters were similar 
between those with and without hyperuricemia. 
However, the former had more history of 
hypertension than the latter respectively, p=0.01. 
Spearman' rho correlation analysis of serum uric 
acid with other parameters done for the study 
subjects did not show any significant association 
with serum uric acid level (Table 4). 
DISCUSSION
The prevalence of hyperuricemia from 
this study is comparable with that of Isezuo et al 
and Ogbera et al even though they worked on 
high risk groups (20, 21). This study was 
conducted among the urban populace and life 
styles associated with urbanization is a known 
risk factor for hyperuricemia. A significant 
number of the participants also had historical 
evidence of long standing systemic hypertension. 
Elevated serum uric acid level has been found to 
be commoner among males (9,24,29)  in line with 
the findings in the present study. 
The result of this study showed that uric 
acid levels increase with advancing age which is 
consistent with findings of previous studies 
(7 18 30). Renal excretion and clearance of uric , ,
acid decreases with age and the additional risk of 
arteriolosclerosis in old age especially in 
hypertensive individuals is contributory.  
Hyperuricemia revealed a gender bias as fewer 
females had elevated uric acid level than males. 
The uricosuric effect of estrogen is said to 
account for lower incidence of hyperuricemia in 
females with increasing age prior to menopause 
(29).
Hyperuricemia results as a consequence 
of increased production or decreased excretion of 
uric acid (10). Elevated serum uric acid level 
induces vascular inflammation and arterial 
endothelial wall damage with increased risk of 
 
atherosclerosis (11,15). The consequent 
endothelial dysfunction and reduction in the 
concentration of endothelial nitric oxide are the 
proposed mechanisms by which uric acid is 
associated with cardiovascular risk or clustering 
 
of risk factors designated “metabolic syndrome”.  
However, the contribution of hyperuricemia to 
atherosclerotic vascular disease still remains 
controversial (12,15). Some studies argue that 
observed association between hyperuricemia and 
components of metabolic syndrome were indirect 
 and coincidental (12,13), while others 
documented  overwhelming evidence of  strong 
correlation between them (11,14,16,21). 
C o n s e q u e n t l y,  t h e  a s s u m p t i o n  t h a t  
hyperuricemia is a risk factor of some component 
of metabolic syndrome and renal dysfunction is 
no longer in dispute (10,25,26,28). 
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The present study interestingly showed that 
normouricemic and hyperuricemic subjects had 
similar prevalence of diabetes mellitus, obesity 
and impaired renal function but the latter had 
more history of hypertension than the former. 
This may be as a result of the fact that this survey 
was not among high risk group of patients, 
although the association between hyperuricemia 
and early phases of some components of 
metabolic syndrome has been shown to be 
 inconsistent (17). There was no statistical 
significance in correlation analysis for uric acid 
with Age, BMI, SBP,
DBP, and urea and serum creatinine in this study. 
In a related study by Alikor et al, similar 
correlation analysis had statistical significance 
with waist circumference, total cholesterol, low 
density lipoprotein and gender (24). The 
foregoing observations and taking cognizance of 
the fact that more subjects with historical 
evidence of hypertension had hyperuricemia 
underscore the need for more comprehensive 
study of uric acid level in hypertensive patients.
CONCLUSION
Hyperuricemia is common among the study 
subjects especially among male gender and 
advancing age. The causal relationship of 
hyperuricemia and cardiovascular events still 
remains a contentious issue as the prevalence of  
type2DM, obesity and kidney dysfunction were  
s imilar  between hyperuricemic  and 
normouricemic subjects. It was not feasible to 
determine threshold to commence treatment for 
elevated uric acid level from this study. A larger 
population size and multicentre research is 
required to prove a link between hyperuricemia 
and some components of metabolic syndrome.  
Conflict of interest: No conflict of interest 
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Age (years)                    28.5 (6.8)               27.6 (4.3)         29.7 (9.2)               0.06
 
BMI (Kg/m2)                24.04 (4.5)               23.4 (3.7)       24.40 (5.4)               0.03*
 
WC (cm)                        83.5 (9.0)               83.6 (8.4)       83.4 (10.4)               0.90
 
WHR                              1.06 (0.4)               1.  07 (0.4)         1.04 (0.4)               0.70
 
SBP(mmHg)               117.8 (14.0)           118.9 (13.6)     116.3 (14.4)               0.26
 
DBP(mmHg)                77.1 (10.2)               77.9 (9.6)       75.9 (11.0)                0.21  
 
RBS(mmol/l)    
           
   6.3 (2.8)                 5.9 (1.8)           6.9 (3.7)               0.07
 
Urea (mmol/l)                   5.1 (2.1)                 4.9 (2.1)           5.2 (2.1)               0.43
 
Creatinine(umol/l)            1.0 (0.3)                 1.1 (0.3) 
           
           1.0 (0.3)               0.04*
 
Uric acid (mmol/l)             5.1 (1.7)                 5.2 (1.8)           4.9 (1.6)               0.25
 
Hyperuricaemia (N%)  33 (20.5%)             22 (23.2%)          11 (16.7)               0.049
 
Proteinuria (N%)             45 (28%)             28 (29.5%)    
   
       17 (25.8%)                0.6
 
Haematuria                      9 (5.6%)                    0 (0%)          9 (5.6%)  
 
KEY : BMI=Body mass index, WC=waist circumference, WHR= waist hip ratio, SBP=systolic blood 









Table 2: Distribution of serum uric acid by age group of participants
 
Age group (years)                    Frequency                   Serum uric acid (Mean SD)
 
10-19                                        1                    
               
        5.1 (-)
 
20-29                                        130                               5.0 (1.8)
 
30-39                                        16                                 5.1 (1.9)
 
40-49                                          6        
                           
        6.0 (1.8)
 
50-59                                          6                                 6.5 (1.2)
 
60-69                                          2                                 6.3 (1.6)
 
Total                                
       






Table 3: Comparison of participants with hyperuricaemia and normouricaemia
 
Variable                                 Hyperuricaemia (N= 35)     Normouricaemia (N=126)     p -value
 
                              
Mean (SD)                                        Mean (SD)
 
Age (years)                                28.0 (5.9)                                      28.6 (7.1)                 0.62
 
Weight (kg)               
                   
 67.0 (11.0)                                    68.1 (12.1)                 0.64
 
BMI (kg/m2)                               23.3 (3.0)                                      24.1 (4.8)                 0.24
 
WC (cm)                             
          
  83.3 (8.5)                                      83.6 (9.2)                 0.89
 
WHR                                        1.09 (0.43)                                    1.05 (0.39)                 0.67
 
SBP (mmHg)                               
 
115.3 (9.5)                                   118.5 (14.9)                 0.14
 
DBP mmHg)                              75.5 (7.5)                                     77.6 (10.8)                 0.20
 
RBS (mmol/l)                               6.0 (1.5)   
                              
               6.4 (3.0)                 0.37
 
Urea (mmol/l)                               4.7 (1.6)                                        5.1 (2.1)                 0.30
 
Creatinine (µmol/l)                       1.1 (0.2)        
                           
             1.0 (0.3)                  0.37
 
Hypertension history (N%)        6 (17.9%)                                        8 (6.3%)                  0.01 
 
 
KEY : BMI=Body mass index, WC=waist circumference, WHR= waist hip ratio, SBP=systolic blood 
pressure, DBP= Diastolic blood pressure, RBS=Random blood sugar. 
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Table 4: Spearman’ rho correlation of serum uric acid with other variables
Variables Correlation coefficient P value
Age












































KEY : BMI=Body mass index, SBP=systolic blood pressure, DBP= Diastolic blood pressure, 
RBS=Random blood sugar.
 
  
 
 
 
 
